Showing 7961-7970 of 8886 results for "".
- Valeant Dermatology Announces New Senior Leadership Team in Advance of SILIQ Launchhttps://practicaldermatology.com/news/valeant-dermatology-announces-new-senior-leadership-team-in-advance-of-siliq-launch/2458182/Valeant Dermatology announced a new senior leadership team, led by Bill Humphries, executive vice president and group chairman. The team includes Michael McMyne, vice president of sales; Stacey Williams, vice president of marketing; Charles Hahn,
- The American Society for Laser Medicine and Surgery Names New Officershttps://practicaldermatology.com/news/the-american-society-for-laser-medicine-and-surgery-names-new-officers/2458185/The American Society for Laser Medicine and Surgery (ASLMS) introduced Mathew M. Avram, MD, JD, as its new President at the Annual Conference in April. Dr. Avram succeeds Kristen M. Kelly, MD, who now serves as the Society’s Past President. The 2017-18 ASLMS Executive Committee also i
- BERG and debra of America Partner to Raise Awareness of EBhttps://practicaldermatology.com/news/berg-and-debra-of-america-partner-to-raise-awareness-of-eb/2458184/Biopharmaceutical company BERG and the non-profit patient advocacy group Dystrophic Epidermolysis Bullosa Research Association of America (debra of America) are partnering up to help patients and families affecte
- Study: Smiling May Not Make Us Appear Younger After Allhttps://practicaldermatology.com/news/study-smiling-may-not-make-us-appear-younger-after-all/2458186/Conventional wisdom suggests that smiling makes you appear younger, but researchers at Ben-Gurion University of the Negev in Israel beg to differ. People who smile are actually perceived as older than those with a deadpan or surprised expression, according
- Unilever Ventures Invests in Nutrafolhttps://practicaldermatology.com/news/unilever-ventures-invests-in-nutrafol/2458189/Unilever Ventures, the venture-capital and private-equity arm of consumer packaged goods conglomerate, has emerged as lead investor at the conclusion of series A financing round for Nutrafol®. Investment platform CircleUp made an initial introduction to
- FDA Accepts Aclaris Therapeutics' NDA for Topical Treatment of Seborrheic Keratosishttps://practicaldermatology.com/news/fda-accepts-aclaris-therapeutics-nda-for-topical-treatment-of-seborrheic-keratosis/2458188/The FDA has accepted Aclaris Therapeutics' New Drug Application (NDA) for A-101 40% topical solution, an investigational drug for the potential treatment of seborrheic keratosis (SK). The NDA acceptance by the FDA in its 74-day letter indicates that the application is sufficiently complete to
- Alastin to Present Study Results Demonstrating Anti-aging and Procedure Enhancement Results of TriHex Technologyhttps://practicaldermatology.com/news/alastin-to-present-study-results-demonstrating-effectiveness-of-trihex-technology-for-post-laser-treatment-care/2458197/Alastin Skincare, Inc. will present data on three new studies at the 7th Annual Summit in Aesthetic Medicine meeting in Newport Beach, CA (May 5-7, 2017). "As part of our commitment to generate scientific data related to our Alastin Skincare products and technology, we have been work
- Image Skincare Introduces Organic Suncare Productshttps://practicaldermatology.com/news/image-skincare-introduces-organic-sunscreen-products/2458200/Image Skincare recently introduced two new Prevention + suncare products to protect the skin from the sun and other environmental factors. Prevention + Sport Sunscreen Spray is enriched with plant-derived stem cells and formulated for superior UVA/UVB and Infrared protection during
- BioPharmX Reports Positive Topline Results of BPX-01 Topical Minocycline for Acnehttps://practicaldermatology.com/news/biopharmx-reports-positive-topline-results-of-bpx-01-topical-minocycline-for-acne/2458198/BioPharmX Corporation’s topical minocycline for acne, BPX-01, achieved its primary endpoint in a phase 2b clinical trial. There were statistically significant reductions in non-nodular inflammatory acne lesions when compared to vehicle in both the 1 percent and 2 percent doses of BP
- Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosahttps://practicaldermatology.com/news/abeona-therapeutics-provides-update-on-eb-101-gene-therapy-for-severe-form-of-epidermolysis-bullosa/2458202/Abeona Therapeutics, Inc. has announced updated clinical data from the ongoing Phase 1/2 clinical trial for the EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB), a severe fo